- For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size.
- What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity.
- The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.
Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
At a glance
- Company
- Cardio Diagnostics Holdings
- Ticker
- NASDAQ: CDIO
- Location
- Chicago, United States
Key figures
- Forecast U.S. cardiovascular health care costs in 2020
- $393 billion
- Forecast U.S. cardiovascular health care costs by 2050
- $1.4 trillion
- U.S. cardiovascular disease deaths in 2022
- more than 940,000
- Reported frequency of U.S. cardiovascular disease deaths
- one person every 34 seconds
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What technologies does Cardio Diagnostics use to assess coronary heart disease?
The release says the Chicago-based company applies artificial intelligence, epigenetics and genetics to cardiovascular medicine. It describes the approach as using a blood draw to detect coronary heart disease, including forms the release says standard diagnostic methods may miss. It does not provide details about the test’s specific markers or how its analysis works.
What does the release say about the projected cost of cardiovascular disease?
The release cites a forecast that annual U.S. health care costs for cardiovascular conditions will rise from $393 billion in 2020 to $1.4 trillion by 2050. It presents those costs as part of the wider health burden the company aims to address; the forecast is not a company-specific revenue or cost estimate.
How can epigenetics and genetics contribute to medical testing?
Genetics examines information in a person’s DNA, including inherited variations. Epigenetics studies changes that influence how genes are switched on or off without changing the underlying DNA sequence. In medical testing, information from both fields can be analyzed alongside other signals to help assess health conditions, though the role and accuracy depend on the particular test.
Earlier from Cardio Diagnostics Holdings
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’
